SELLAS Life Sciences Group Inc. Stock News

SELLAS Life Sciences Group, Inc. is a late-stage biopharmaceutical company developing novel cancer immunotherapies. Sellas is currently progressing two therapeutics GalinPepimut-S (Phase 3, Fast Track

Shares of SLS stock are up after SELLAS Life Sciences was mentioned heavily on Reddit. Who is this company?

The stock price of Sellas Life Sciences Group Inc (NASDAQ: SLS) is trading at over 50% pre-market today as of 4:37 AM ET. This is why it happened.

-  Phase 3 REGAL Study of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) Patients Underway in United States and Europe  -

Breast cancer is the second leading cause of death of women in the U.S. alone. Given the prevalence of the disease, it's no surprise that numerous pharmaceutical and biotech companies are searching fo

- Early Data from Study of GPS in Combination with Keytruda® in Patients with Advanced WT1(+) Ovarian Cancer Shows Disease Control Rate of 87.5% at a Median Follow-up of 9.4 Weeks  and 100% Progress

- Proceeds Received from Registered Direct Offering, Warrant Exercises and Upfront Fee from China Out-licensing - 

NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the developme

Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduc

– Immune Stimulation Augmented by +1,300% at 6-months Post-NPS Treatment –

- SELLAS to Potentially R eceive Up To $ 202 Million, Inclusive of $7.5 Million Upfront License Fee and $ 8 Million Near-term Milestone s, plus Tiered Royalties -

- Received IM PD A pproval to C ommence E nrollment in France for P ivotal Phase 3 S tudy of G alinpepimut -S in A cute M yeloid L eukemia P atients -